Physician profile
Robert Canonico
NPI 1003956905
$3,062.30
in general payments reported to CMS, 2019-2025
14 companies · $778 in 2025
The $778 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $173 · 2021: $282 · 2022: $538 · 2023: $691 · 2024: $386 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $861.57 | 2021-2025 | Tysabri, Vumerity, Plegridy |
| Abbvie INC. | $462.18 | 2022-2024 | Botox |
| Jazz Pharmaceuticals INC. | $394.23 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $244.10 | 2025 | Ultomiris |
| Genentech USA, INC. | $210.88 | 2024-2025 | Ocrevus, Evrysdi, Ocrevus Zunovo |
| Genentech, INC. | $170.69 | 2022-2023 | Ocrevus, Activase |
| Merz North America, INC. | $132.37 | 2019 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $110.00 | 2021 | |
| Eisai INC. | $87.38 | 2025 | |
| Novartis Pharmaceuticals Corporation | $82.27 | 2019 | |
| Emd Serono, INC. | $80.21 | 2025 | |
| Lilly USA, LLC | $53.12 | 2021 | |
| Livanova USA, INC. | $48.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Canonico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.